These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 24717090)

  • 1. Factor VIII therapy for hemophilia A: current and future issues.
    Aledort L; Ljung R; Mann K; Pipe S
    Expert Rev Hematol; 2014 Jun; 7(3):373-85. PubMed ID: 24717090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Issues complicating precision dosing for factor VIII prophylaxis.
    Valentino LA; Turecek PL; Gritsch H; Butenas S; Mann KG
    Transfus Apher Sci; 2018 Aug; 57(4):472-479. PubMed ID: 30139569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis.
    Croteau SE; Cook K; Sheikh L; Chawla A; Sammon J; Solari P; Kim B; Hinds D; Thornburg CD
    J Manag Care Spec Pharm; 2021 Mar; 27(3):316-326. PubMed ID: 33645244
    [No Abstract]   [Full Text] [Related]  

  • 6. Hemophilia A in the third millennium.
    Franchini M; Mannucci PM
    Blood Rev; 2013 Jul; 27(4):179-84. PubMed ID: 23815950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Will gene therapy trump factor treatment in hemophilia?
    Rangarajan S; Aledort L
    Expert Rev Hematol; 2013 Feb; 6(1):43-8. PubMed ID: 23373779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemophilia A--from basic science to clinical practice.
    Klinge J; Ananyeva NM; Hauser CA; Saenko EL
    Semin Thromb Hemost; 2002 Jun; 28(3):309-22. PubMed ID: 12098093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of natural VWF/FVIII complex concentrates in contemporary haemophilia care: a guideline for the next decade.
    Mannucci PM
    Haemophilia; 2012 May; 18 Suppl 2():2-7. PubMed ID: 22530573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.
    Oldenburg J; Chambost H; Liu H; Hawes C; You X; Yang X; Newman V; Robinson TM; Hatswell AJ; Hinds D; Santos S; Ozelo M
    Adv Ther; 2024 Jun; 41(6):2267-2281. PubMed ID: 38616241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
    Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
    Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune tolerance induction in patients with hemophilia A.
    Astermark J
    Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A.
    Castaman G; Linari S
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):143-151. PubMed ID: 29257899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
    Amiral J; Seghatchian J
    Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological considerations of plasma-derived and recombinant factor VIII immunogenicity.
    Lai J; Hough C; Tarrant J; Lillicrap D
    Blood; 2017 Jun; 129(24):3147-3154. PubMed ID: 28432221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular genetics of hemophilia A].
    De Brasi CD; Slavutsky IR; Larripa IB
    Medicina (B Aires); 1996; 56(5 Pt 1):509-17. PubMed ID: 9239887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.